BidaskClub upgraded shares of Medpace (NASDAQ:MEDP) from a buy rating to a strong-buy rating in a research report released on Thursday, BidAskClub reports.

A number of other equities analysts also recently commented on MEDP. SunTrust Banks boosted their target price on shares of Medpace from $95.00 to $124.00 and gave the stock a hold rating in a report on Wednesday. Zacks Investment Research upgraded shares of Medpace from a sell rating to a hold rating in a report on Wednesday, May 20th. Credit Suisse Group boosted their target price on shares of Medpace from $92.00 to $114.00 and gave the stock an outperform rating in a report on Tuesday, July 28th. Wolfe Research downgraded shares of Medpace from an outperform rating to a peer perform rating and set a $91.00 target price for the company. in a report on Wednesday, May 13th. Finally, Robert W. Baird upgraded shares of Medpace from an underperform rating to a neutral rating and set a $83.00 target price for the company in a report on Monday, June 8th. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the stock. Medpace has a consensus rating of Buy and an average target price of $103.29.

Shares of MEDP stock traded down $0.15 on Thursday, hitting $119.35. The stock had a trading volume of 455,621 shares, compared to its average volume of 390,909. The company has a quick ratio of 0.89, a current ratio of 0.94 and a debt-to-equity ratio of 0.16. The business has a 50 day moving average price of $96.91 and a 200 day moving average price of $88.75. The company has a market cap of $4.23 billion, a PE ratio of 42.47 and a beta of 1.22. Medpace has a one year low of $58.72 and a one year high of $144.49.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, July 27th. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.40 by $0.28. The firm had revenue of $205.00 million during the quarter, compared to the consensus estimate of $181.17 million. Medpace had a return on equity of 16.05% and a net margin of 12.11%. The firm’s quarterly revenue was down 4.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.81 earnings per share. Equities research analysts expect that Medpace will post 3.21 EPS for the current year.

In related news, CEO August J. Troendle sold 8,582 shares of the company’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $100.40, for a total value of $861,632.80. Also, major shareholder Medpace Investors, Llc sold 214,499 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $127.23, for a total value of $27,290,707.77. Following the completion of the sale, the insider now owns 7,542,057 shares in the company, valued at approximately $959,575,912.11. The disclosure for this sale can be found here. Insiders have sold 669,153 shares of company stock worth $77,389,817 in the last 90 days. Insiders own 26.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Wasatch Advisors Inc. boosted its position in Medpace by 26.9% in the first quarter. Wasatch Advisors Inc. now owns 2,290,382 shares of the company’s stock valued at $168,068,000 after buying an additional 485,397 shares during the last quarter. State Street Corp boosted its position in Medpace by 7.8% in the 1st quarter. State Street Corp now owns 859,618 shares of the company’s stock worth $63,079,000 after purchasing an additional 62,312 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its position in Medpace by 27.6% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 726,816 shares of the company’s stock worth $53,334,000 after purchasing an additional 157,308 shares in the last quarter. Geode Capital Management LLC boosted its position in Medpace by 5.5% in the 1st quarter. Geode Capital Management LLC now owns 450,923 shares of the company’s stock worth $33,088,000 after purchasing an additional 23,691 shares in the last quarter. Finally, Ranger Investment Management L.P. boosted its position in Medpace by 31.1% in the 1st quarter. Ranger Investment Management L.P. now owns 436,156 shares of the company’s stock worth $32,005,000 after purchasing an additional 103,591 shares in the last quarter. Hedge funds and other institutional investors own 79.83% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

See Also: How to invest in a bear market

Analyst Recommendations for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.